- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02473211
SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients
March 16, 2018 updated by: Humanity and Health Research Centre
Efficacy and Safety of Sofosbuvir Plus Daclatasvir in Chinese Treatment-experienced Patients With Chronic Genotype 1b HCV Infection
For those chronic hepatitis C patients, who are interferon-ineligible or intolerant, there is a burning need for the development of pan-oral interferon-free regimen.
The investigators examine the efficacy and safety of sofosbuvir, a NS5B nucleotide polymerase inhibitor and daclatasvir, an NS5A replication complex inhibitor in Chinese treatment-experienced cirrhosis patients with chronic G1b infection.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Chinese genotype 1b HCV treatment-experienced cirrhotic patients are recruited and treated with 12 weeks sofosbuvir 400 mg daily plus daclatasvir 60 mg daily.
At baseline, liver stiffness measurement (LSM) using transient elastography (FibroScan®) is used to assess liver fibrosis and the single nucleotide polymorphism ofinterferon-λ 3 (IL-28, rs12979860, C or T) and IFLN4 (ss469415590, TT or ΔG) is determined.
Serial measurement of plasma HCV RNA levels are performed with the use of the COBAS TaqMan real-time assay (Roche version 2.0), at baseline, Day 2,4 and 7, week 2,4 and 12, post-treatment week 12.
The primary efficacy end point is a sustained virologic response 12 weeks after the end of treatment (SVR12).
Study Type
Interventional
Enrollment (Actual)
106
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100039
- Liver Fibrosis Diagnosis and Treatment Centre, 302 Hospital
-
-
Hong Kong
-
Hong Kong, Hong Kong, China, 00852
- Humanity and Health GI and Liver Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients chronically infected with HCV Genotype-1b;
- Documented evidence of relapse after completion of previous course of interferon-based regimen with or without ribavirin;
- HCV RNA level greater than 10,000 IU/ml at screening;
- Patients with compensated cirrhosis are permitted.
Exclusion Criteria:
- Current or prior history: Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with treatment, assessment or compliance with the protocol; individuals currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded;
- Screening ECG with clinically significant abnormalities;
- Laboratory results outside of acceptable ranges at screening;
- Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SOF+DCV
Participants will receive Sofosbuvir (SOF) 400 mg and Daclatasvir (DCV) 60 mg daily for 12 weeks.
|
Sofosbuvir 400 mg tablet administered once daily
Other Names:
Daclatasvir 60mg tablet administered once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants with sustained virologic response 12 weeks after the end of treatment (SVR12)
Time Frame: Post treatment Week 12
|
SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) (15 IU/ml) 12 weeks following the last dose of study drug
|
Post treatment Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: George KK Lau, MD, Humanity and Health GI and Liver Centre
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (Actual)
December 31, 2017
Study Completion (Actual)
March 15, 2018
Study Registration Dates
First Submitted
June 12, 2015
First Submitted That Met QC Criteria
June 12, 2015
First Posted (Estimate)
June 16, 2015
Study Record Updates
Last Update Posted (Actual)
March 19, 2018
Last Update Submitted That Met QC Criteria
March 16, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H&H_SOF plus DCV treatment
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis C Infection
-
University Health Network, TorontoCompletedChronic Hepatitis C Virus InfectionCanada
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...Recruiting
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
PharmaEssentiaCompletedChronic Hepatitis C Virus InfectionKorea, Republic of, Taiwan, China
-
Janssen R&D IrelandTerminated
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
Gilead SciencesCompletedChronic Hepatitis C InfectionNew Zealand
-
Humanity and Health Research CentreBeijing 302 HospitalCompletedChronic Hepatitis C InfectionChina
-
Humanity and Health Research CentreBeijing 302 HospitalCompletedChronic Hepatitis C InfectionChina
Clinical Trials on Sofosbuvir
-
Assiut UniversityUnknown
-
University of California, San FranciscoCompletedHepatitis C | Transplantation Disease TransmissionUnited States
-
Icahn School of Medicine at Mount SinaiGilead SciencesCompletedHepatitis C | CryoglobulinemiaUnited States
-
Radboud University Medical CenterWithdrawnHCVNetherlands, Germany
-
Fondazione Italiana Linfomi ONLUSCompletedHepatitis C | Indolent B-cell LymphomaItaly
-
Third Affiliated Hospital, Sun Yat-Sen UniversityCompletedChronic Hepatitis C (Disorder)
-
Institute of Liver and Biliary Sciences, IndiaTerminated
-
Third Affiliated Hospital, Sun Yat-Sen UniversityCompleted
-
Brigham and Women's HospitalRecruiting
-
Alexandria UniversityCompletedHepatocellular Carcinoma | Hepatitis C | Neoplasm Recurrence | Treatment ComplicationEgypt